Gouédard O, Gaudet E, Blanc J, Ponchon P, Elghozi J L
Laboratoire de pharmacologie, CNRS URA 1482, faculté de médecine Necker-Enfants Malades, Paris.
Arch Mal Coeur Vaiss. 1996 Aug;89(8):1013-7.
The aim of this study was to investigate, using spectral analysis, 1) the blood pressure (BP) variability changes in the conscious rat during blockade of nitric oxide (NO) synthesis by the L-arginine analogue L-NAME; 2) the involvement of the renin-angiotensin system in these modifications, using the angiotensin II AT1-receptor antagonist losartan. The blockade of the NO synthesis was made by infusion for 1 hour of a low dose (10 micrograms/kg/min, i.v.; n = 10) and a high dose (100 micrograms/kg/min, i.v.; n = 10) of L-NAME. The same treatment was applied in two further groups (n = 2 x 10) after a bolus of losartan (10 mg/kg, i.v.). The low dose of L-NAME increased systolic BP (SBP) on and after thirty min of infusion (+10 +/- 3 mmHg; p < 0.01). BP reached a maximum value 5 min after stopping L-NAME administration (+20 +/- 4 mmHg; p < 0.001). With the high dose of L-NAME, SBP increased immediately (5 min: +8 +/- 2 mmHg; p < 0.05) and reached a maximum at 40 min (+53 +/- 4 mmHg; p < 0.001); a bradycardia was observed (60 min: -44 +/- 13 batt/min; p < 0.01). The low dose of L-NAME increased the low-frequency component (LF: 0.02-0.2 Hz) of SBP variability (50 min: 6.7 +/- 1.7 mmHg2 vs 3.4 +/- 0.5 mmHg2; p < 0.05). The high dose of L-NAME increased the LF component (40 min: 11.7 +/- 2 mmHg2 vs 2.7 +/- 0.5 mmHg2; p < 0.001) and decreased the mid frequency (MF: 0.2-0.6 Hz) component (60 min: 1.14 +/- 0.3 mmHg2 vs 1.7 +/- 0.1 mmHg2, p < 0.05) of SBP. Losartan did not modify BP levels but had a tachycardic effect (+33 +/- 10 batt/min; n = 27). Moreover, losartan increased MF oscillations of SBP (4.26 +/- 0.49 mmHg2 vs 2.43 +/- 0.25 mmHg2; p < 0.001; n = 27). Losartan prevented the BP rise provoked by the low-dose of L-NAME and delayed the BP rise provoked by the high-dose. Losartan prevented the amplification of the LF oscillations of SBP induced by the L-NAME; the decrease of the MF oscillations of SBP induced by the L-NAME was reinforced after losartan). We concluded that the renin-angiotensin system is involved in the increase of variability of SBP in the LF range which resulted from the withdrawal of the vasodilatating influence of NO. We proposed that NO could counterbalance LF oscillations provoked by the activity of the renin-angiotensin system.
本研究旨在通过频谱分析,调查:1)L-精氨酸类似物L-NAME阻断一氧化氮(NO)合成过程中清醒大鼠的血压(BP)变异性变化;2)使用血管紧张素II AT1受体拮抗剂氯沙坦,研究肾素-血管紧张素系统在这些变化中的作用。通过静脉输注低剂量(10微克/千克/分钟,n = 10)和高剂量(100微克/千克/分钟,n = 10)的L-NAME 1小时来阻断NO合成。在给予氯沙坦(10毫克/千克,静脉推注)后,对另外两组(n = 2×10)进行相同处理。低剂量的L-NAME在输注30分钟及之后升高收缩压(SBP)(+10±3 mmHg;p < 0.01)。停止给予L-NAME后5分钟血压达到最大值(+20±4 mmHg;p < 0.001)。使用高剂量的L-NAME时,SBP立即升高(5分钟时:+8±2 mmHg;p < 0.05),并在40分钟时达到最大值(+53±4 mmHg;p < 0.001);观察到心动过缓(60分钟时:-44±13次/分钟;p < 0.01)。低剂量的L-NAME增加了SBP变异性的低频成分(LF:频率0.02 - 0.2赫兹)(50分钟时:6.7±1.7 mmHg² 对比 3.4±0.5 mmHg²;p < 0.05)。高剂量的L-NAME增加了LF成分(40分钟时:11.7±2 mmHg² 对比 2.7±0.5 mmHg²;p < 0.001),并降低了SBP的中频(MF:频率0.2 - 0.6赫兹)成分(60分钟时:1.14±0.3 mmHg² 对比 1.7±0.1 mmHg²,p < 0.05)。氯沙坦未改变血压水平,但有心动过速作用(+33±10次/分钟;n = 27)。此外,氯沙坦增加了SBP的MF振荡(4.26±0.49 mmHg² 对比 2.43±0.25 mmHg²;p < 0.001;n = 27)。氯沙坦可预防低剂量L-NAME引起的血压升高,并延迟高剂量L-NAME引起的血压升高。氯沙坦可预防L-NAME诱导的SBP的LF振荡增强;氯沙坦使用后,L-NAME诱导的SBP的MF振荡降低更为明显。我们得出结论,肾素-血管紧张素系统参与了因NO血管舒张作用减弱导致的SBP在LF范围内变异性增加。我们提出,NO可抵消肾素-血管紧张素系统活动引发的LF振荡。